Cranial Nerve Diseases: Clinical Trials

210 trials for Cranial Nerve Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

125 completed, 25 recruiting, 20 terminated, 17 unknown. 210 Phase 1, 63 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1210Completed 125, Recruiting 25, Terminated 20, Unknown 17, Not yet recruiting 10, Active not recruiting 6, Withdrawn 6, Suspended 1
Phase 263Completed 27, Recruiting 12, Unknown 10, Terminated 7, Not yet recruiting 4, Active not recruiting 3

Follow Cranial Nerve Diseases: new trials by email Literature Review of Cranial Nerve Diseases trials Research Report on Cranial Nerve Diseases

Trials (filtered) newest first · largest first

All 210 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT)
Prednisone, Ajovy, Manual Therapy - Cranial Nerve Injury, Oropharyngeal Cancer
Phase 1Not yet recruitingM.D. Anderson Cancer Center482027-03-012026-09-21
Safety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder
Anti-BAFFR CART - Neuromyelitis Optica Spectrum Disorder
Phase 1 / Phase 2Not yet recruitingTianjin Medical University General Hospital202026-12-012026-10-16
Single Dose 4-Aminopyridine for Diagnosing Recurrent Laryngeal Nerve Paralysis Continuity After Trauma
4-Aminopyridine - Vocal Cord Paralysis, Recurrent Laryngeal Nerve Palsy
Phase 1Not yet recruitingMilton S. Hershey Medical Center502026-12-012026-09-21
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease
CTX112 - Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica
Phase 1 / Phase 2Not yet recruitingCRISPR Therapeutics2202026-11-012026-10-22
A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve Damage
ASP2767, Sham ASP2767, Prophylactic Regimen A - Glaucoma
Phase 1 / Phase 2RecruitingAstellas Pharma Global Development, Inc.1562026-10-072026-11-13
Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial
Tributyrin, Placebo - Parkinson Disease, Multiple System Atrophy
Phase 1 / Phase 2RecruitingPrabesh Kanel152026-10-012026-11-05
RP-008 in Combination With Daily Oral Varenicline for the Treatment of Trigeminal Neuralgia
RP-008, Varenicline tartrate - Trigeminal Neuralgia
Phase 1 / Phase 2RecruitingKriya Therapeutics, Inc.242026-09-102026-10-23
Luvometinib in Combination With Serplulimab for NF2-Related Tumors
Luvometinib, Serplulimab - NF2-related Schwannomatosis, NF2
Phase 1 / Phase 2Not yet recruitingBeijing Tiantan Hospital302026-07-312026-07-16
Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II
Trineumin - Neurofibromatosis Type II, NF2
Phase 1 / Phase 2Not yet recruitingPRG Science & Technology Co., Ltd.252026-07-012026-01-23
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
CD20/BCMA-directed CAR-T cells Autologous 2nd generation - Multiple Sclerosis (MS), Myasthenia Gravis (MG)
Phase 1Not yet recruitingThe Affiliated Hospital of Qingdao University182026-07-012026-06-30
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Universal CD19 CAR-γδT Cell Injection, Cyclophosphamide, Fludarabine - Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD)
Phase 1RecruitingTongji Hospital62026-04-012026-05-12
Pilot Study of the Efficacy of Nicotinamide (Vitamin B3) in Leber's Hereditary Optic Neuropathy
Nicotinamide treatment - Leber Hereditary Optic Neuropathy (LHON), Leber's Hereditary Optic Neuropathy (LHON)
Phase 1Not yet recruitingUniversity Hospital, Angers132026-04-012025-12-18
Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)
ER-100 epigenetic therapy - Open Angle Glaucoma (OAG), NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)
Phase 1RecruitingLife Biosciences Inc.182026-03-022026-05-19
A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy
CD20/BCMA-directed CAR-T cells - Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD)
Phase 1Not yet recruitingHuashan Hospital152026-02-012026-01-15
Home-based Vision Therapy
Virtual-reality convergence training game - Convergence Insufficiency
Phase 1RecruitingVA Office of Research and Development452026-01-142026-01-20
Trial of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease or Primary Tauopathies
ARO-MAPT-SC, Placebo - Alzheimer Disease, Tauopathies
Phase 1 / Phase 2RecruitingArrowhead Pharmaceuticals1602025-11-182026-11-10
Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle)
PYC-001 - OPA1 Gene Mutation, Autosomal Dominant Optic Atrophy
Phase 1 / Phase 2RecruitingPYC Therapeutics242025-09-302026-06-29
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy - Melanoma, Medullary Thyroid Cancer
Phase 1 / Phase 2RecruitingUniversity of Arizona302025-09-082026-10-06
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
[212Pb]VMT-alpha-NET, [203Pb]VMT-alpha-NET, 68Ga-DOTATATE - Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma
Phase 1RecruitingNational Cancer Institute (NCI)1202025-08-192026-10-06
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
Azercabtagene zapreleucel (azer-cel) - B-cell Mediated Autoimmune Disorders
Phase 1RecruitingTG Therapeutics, Inc.1002025-05-062026-10-27

Showing 20 of 210. Sign in to see all of them.

Narrower conditions

Astrocytoma (49)  ·  Optic Nerve Glioma (48)  ·  Medulloblastoma (46)  ·  Familial ependymoma (40)  ·  Oligodendroglioma (36)  ·  Choroid Plexus Neoplasms (34)  ·  Neuromyelitis Optica (32)  ·  Central Nervous System Neoplasms (31)  ·  Esthesioneuroblastoma, Olfactory (29)  ·  Squamous Cell Carcinoma of Head and Neck (23)  ·  Supranuclear Palsy, Progressive (23)  ·  Salivary Gland Neoplasms (21)  ·  Carcinoma, Non-Small-Cell Lung (17)  ·  Neuroblastoma (17)  ·  Neuroectodermal Tumors, Primitive, Peripheral (17)

Broader conditions

Nervous System Diseases (210)  ·  Eye Diseases (148)  ·  Optic Nerve Diseases (110)  ·  Neoplasms by Site (96)  ·  Neoplasms (91)  ·  Neoplasms by Histologic Type (86)  ·  Neoplasms, Nerve Tissue (86)  ·  Neuroectodermal Tumors (86)  ·  Neoplasms, Germ Cell and Embryonal (85)  ·  Central Nervous System Diseases (81)  ·  Neoplasms, Glandular and Epithelial (79)  ·  Neoplasms, Neuroepithelial (76)  ·  Brain Diseases (71)  ·  Nervous System Neoplasms (70)

Interventions

Filgrastim (12)  ·  Carboplatin (9)  ·  Temozolomide (9)  ·  Bevacizumab (6)  ·  Docetaxel (6)  ·  Granulocyte Colony-Stimulating Factor (6)  ·  Cetuximab (4)  ·  Cyclophosphamide (4)  ·  Erlotinib Hydrochloride (4)  ·  Etoposide (4)  ·  Irinotecan (4)  ·  Busulfan (3)  ·  Ifosfamide (3)  ·  Methylprednisolone (3)  ·  O(6)-benzylguanine (3)

Sponsors

National Cancer Institute (NCI) (26)  ·  Pediatric Brain Tumor Consortium (8)  ·  Children's Oncology Group (6)  ·  Biogen (5)  ·  National Institutes of Health Clinical Center (CC) (5)  ·  University of California, San Francisco (5)  ·  Memorial Sloan Kettering Cancer Center (4)  ·  National Eye Institute (NEI) (4)  ·  Tianjin Medical University General Hospital (4)  ·  Case Comprehensive Cancer Center (3)  ·  City of Hope Medical Center (3)  ·  Johns Hopkins University (3)  ·  M.D. Anderson Cancer Center (3)  ·  Alexandria University (2)  ·  Invicro (2)

Countries

United States (134)  ·  China (20)  ·  Canada (15)  ·  United Kingdom (12)  ·  Germany (6)  ·  Spain (5)  ·  Australia (4)  ·  Belgium (4)  ·  Iran (4)  ·  Egypt (3)  ·  France (2)  ·  Greece (2)  ·  Israel (2)  ·  New Zealand (2)  ·  Norway (2)

Top investigators

Adam Boxer, MD, PhD (3)  ·  Michael Levy, MD, PhD (3)  ·  Scot C. Remick, MD (3)  ·  Andrew Stephens, MD, PhD (2)  ·  Elizabeth Fox, MD (2)  ·  Erling A Tronvik, PhD, MD (2)  ·  Harry T Whelan, MD (2)  ·  Mai ElBahwash, PhD (2)  ·  Mark W. Kieran, MD, PhD (2)  ·  Susan M. Blaney, MD (2)  ·  Aaron Tward, MD (1)

Results publications

PMID 10916328, PMID 15033677, PMID 15793381, PMID 15814645, PMID 16234526, PMID 16533779, PMID 16899778, PMID 16914576, PMID 17634493, PMID 17941066, PMID 18048828, PMID 18281544, PMID 18281546, PMID 18470481, PMID 19065567, PMID 19075272, PMID 19430790, PMID 19838774, PMID 20006669, PMID 20044751, PMID 20049936, PMID 20145168, PMID 20407240, PMID 20460632, PMID 20606544, PMID 21115653, PMID 21211990, PMID 21764821, PMID 22236384, PMID 22294344, PMID 23131255, PMID 23554030, PMID 23623397, PMID 23773637, PMID 23857966, PMID 23868427, PMID 24398093, PMID 24438512, PMID 24457989, PMID 25191939, PMID 25223501, PMID 25342621, PMID 25965900, PMID 26062933, PMID 26606867, PMID 26611425, PMID 26933802, PMID 27143789, PMID 27160012, PMID 27631475

NIH funding

U01CA081457 (9), U01CA097452 (8), P30CA043703 (3), 2017 (2), P30CA033572 (2), U01CA062502 (2), U01CA069856 (2), 2014 (1), 2015 (1), 2016 (1), 2018 (1), 2019 (1), 2025 (1), P30CA008748 (1), P30CA016087 (1)